Evolus operates in the cash-pay medical aesthetics market. Its core business revolves around commercializing specialized aesthetic products, most notably Jeuveau (an injectable neurotoxin used for wrinkle smoothing) and lines of hyaluronic acid (HA) dermal fillers, targeting millennial and cosmetic consumer demographics through direct-to-practice digital platforms.